We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 21, 2020

EASD 2020: REWIND: CV Benefits of Dulaglutide on MACE Are Not Attributable to HbA1C, Weight, or Antihypertensive Effects

Potential mediators of the CV benefit of dulaglutide in the trial were explored.

PracticeUpdate Editorial Team


Further Reading